Discovering metabolic vulnerability using spatially resolved metabolomics for antitumor small molecule-drug...

Area of Science:

• Oncology
• Metabolic Engineering
• Drug Delivery Systems

Background:

• Targeting tumor-specific metabolic vulnerabilities is a promising cancer therapy strategy.
• Metabolic inhibitors face challenges due to cancer cell drug resistance, metabolic plasticity, and heterogeneity.
• Choline metabolism is identified as a highly active metabolic vulnerability across various cancer types.

Purpose of the Study:

• To develop a novel strategy for targeted cancer therapy by exploiting choline metabolism.
• To design and validate choline-modified small molecule-drug conjugates (SMDCs) as a method to deliver chemotherapy drugs.
• To improve tumor targeting, enhance therapeutic efficacy, and reduce the toxicity of chemotherapy drugs.

Main Methods:

• Spatially resolved metabolomics analysis to identify metabolic vulnerabilities.
• Design and synthesis of choline-modified small molecule-drug conjugates (SMDCs).
• In vitro and in vivo evaluation of SMDC druggability, including tumor targeting, inhibition, and toxicity assessments.

Main Results:

• Choline metabolism was identified as a key metabolic vulnerability in cancer.
• Choline-modified SMDCs were successfully designed and demonstrated druggability.
• The strategy enhanced tumor targeting and drug delivery, preserved tumor inhibition, and reduced paclitaxel toxicity.
• Targeted delivery was achieved via highly expressed choline transporters, with site-specific drug release mediated by carboxylesterase.

Conclusions:

• Choline metabolism represents a viable metabolic vulnerability for targeted cancer therapy.
• Choline-modified SMDCs offer a novel approach for precise cancer treatment by exploiting metabolic pathways.
• This strategy provides new insights into developing effective and less toxic cancer therapeutics.